These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 18424307)

  • 21. Severe psoriasis treated with a new macrolide: everolimus.
    Frigerio E; Colombo MD; Franchi C; Altomare A; Garutti C; Altomare GF
    Br J Dermatol; 2007 Feb; 156(2):372-4. PubMed ID: 17223881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythrodermic CD8+ pseudolymphoma during infliximab treatment in a patient with psoriasis: use of cyclosporine as a rescue therapy.
    Safa G; Luce K; Darrieux L; Tisseau L; Ortonne N
    J Am Acad Dermatol; 2014 Oct; 71(4):e149-50. PubMed ID: 25219741
    [No Abstract]   [Full Text] [Related]  

  • 23. Cyclosporine: what clinicians need to know.
    Koo J; Lee J
    Dermatol Clin; 1995 Oct; 13(4):897-907. PubMed ID: 8785893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psoralens and UV-A and UV-B twice weekly for the treatment of psoriasis.
    Diette KM; Momtaz-T K; Stern RS; Arndt KA; Parrish JA
    Arch Dermatol; 1984 Sep; 120(9):1169-73. PubMed ID: 6476854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bath PUVA and psoriasis: is a milder treatment a worse treatment?
    Delrosso G; Bornacina C; Farinelli P; Bellinzona F; Leigheb G; Colombo E
    Dermatology; 2008; 216(3):191-3. PubMed ID: 18182808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference.
    Rosmarin DM; Lebwohl M; Elewski BE; Gottlieb AB;
    J Am Acad Dermatol; 2010 May; 62(5):838-53. PubMed ID: 19932926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Additive effects of calcipotriol and cyclosporine A: from in vitro experiments to in vivo applications in the treatment of severe psoriasis.
    Bagot M; Grossman R; Pamphile R; Binderup L; Charue D; Revuz J; Dubertret L
    C R Acad Sci III; 1994 Mar; 317(3):282-6. PubMed ID: 7994616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use.
    Behnam SM; Behnam SE; Koo JY
    J Drugs Dermatol; 2005; 4(2):189-94. PubMed ID: 15776776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bath-PUVA therapy induces circulating regulatory T cells in patients with psoriasis.
    Saito C; Maeda A; Morita A
    J Dermatol Sci; 2009 Mar; 53(3):231-3. PubMed ID: 19070466
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
    Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
    J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic plaque psoriasis.
    Naldi L; Rzany B
    Clin Evid; 2005 Jun; (13):2070-98. PubMed ID: 16135323
    [No Abstract]   [Full Text] [Related]  

  • 32. Paired comparison of bathwater versus oral delivery of 8-methoxypsoralen in psoralen plus ultraviolet: A therapy for chronic palmoplantar psoriasis.
    Hofer A; Fink-Puches R; Kerl H; Quehenberger F; Wolf P
    Photodermatol Photoimmunol Photomed; 2006 Feb; 22(1):1-5. PubMed ID: 16436174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Nail psoriasis].
    Gueissaz F; Borradori L; Dubertret L
    Ann Dermatol Venereol; 1992; 119(1):57-63. PubMed ID: 1562156
    [No Abstract]   [Full Text] [Related]  

  • 34. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy.
    Fortune DG; Richards HL; Kirby B; McElhone K; Markham T; Rogers S; Main CJ; Griffiths CE
    Arch Dermatol; 2003 Jun; 139(6):752-6. PubMed ID: 12810506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis.
    Lago E; Carneiro S; Cuzzi T; Magalhães G; Cássia F; Pessanha F; Ramos-e-Silva M
    J Cutan Pathol; 2007 Jan; 34(1):15-21. PubMed ID: 17214849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions.
    Opmeer BC; Heydendael VM; deBorgie CA; Spuls PI; Bossuyt PM; Bos JD; de Rie MA
    J Clin Epidemiol; 2007 Jul; 60(7):696-703. PubMed ID: 17573985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in psoriasis treatment.
    Feldman S
    Dermatol Online J; 2000 Sep; 6(1):4. PubMed ID: 11328614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of psoralen-UVA (PUVA) topical therapy in palmoplantar psoriasis: a report on 48 patients.
    Carrascosa JM; Plana A; Ferrándiz C
    Actas Dermosifiliogr; 2013 Jun; 104(5):418-25. PubMed ID: 23680012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes of skin blood flow and color on lesional and control sites during PUVA therapy for psoriasis.
    Suh DH; Kwon TE; Kim SD; Park SB; Kwon OS; Eun HC; Youn JI
    J Am Acad Dermatol; 2001 Jun; 44(6):987-94. PubMed ID: 11369911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiproliferative, antiangiogenic and apoptotic effect of photochemotherapy (PUVA) in psoriasis patients.
    Ceović R; Pasić A; Lipozencić J; Jakić-Razumović J; Szirovicza L; Kostović K
    Coll Antropol; 2007 Jun; 31(2):551-6. PubMed ID: 17847938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.